This document summarizes research on drug-induced anaphylaxis in Latin America. Some key findings include:
- Drugs are a leading cause of anaphylaxis in Latin America, reported in 34% of cases in one study. NSAIDs and beta-lactams are among the most common culprits.
- Studies in Latin America found cardiovascular involvement in over 45% of anaphylaxis cases, and was more frequent in elderly patients. Shock and severe reactions were also more common in the elderly.
- A study of over 800 anaphylaxis cases across Latin America found NSAIDs to be the predominant cause in adults, while beta-lactams were more common in children and
The Future of Allergy and Clinical Immunology Prof. G. Walter Canonica - Con...Juan Carlos Ivancevich
Prof.G.Walter Canonica
Allergy and Respiratory Diseases Clinic
DIMI-‐University of Genoa
Italy
Presidente Congreso SLaai 2015: Dr. Alfonso Cepeda Sarabia
The Future of Allergy and Clinical Immunology Prof. G. Walter Canonica - Con...Juan Carlos Ivancevich
Prof.G.Walter Canonica
Allergy and Respiratory Diseases Clinic
DIMI-‐University of Genoa
Italy
Presidente Congreso SLaai 2015: Dr. Alfonso Cepeda Sarabia
Programa Congreso Para Todos
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015.XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai: 2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Programa Congreso Para Todos
XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015.XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai: 2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015 - http://www.slaai2015.com
Anaphylaxis lecture uihc pulm_grand_round_11_4_2016 Sangil Lee
This is a lecture given to pulm/critical care grand round on 11/4/2016. The lecture content is relevant for clinical practice for first half and some of translational science (research) for second half.
Sesión Académica del CRAIC: Hipersensibilidad a fármacos en Pediatría.Dra. Rosa IvettGuzmán AvilánResidente de Primer año
Dra. med. Gabriela Galindo Rodríguez Profesor Asesor
This is a presentation on anaphylaxis by Michael Rose. Michael is an anaesthetist in Sydney and a leading expert in the world of anaphylaxis. He talks about the basics and recent developments in this field - an area of critical care relevant to us all.
What they didn't tell you about Anaphylaxis 2023.pptxRommie Duckworth
What’s the difference between anaphylactic and anaphylactoid, and should I care? Can a patient have a life-threatening reaction on a first exposure? What are the most important ALS medications for anaphylaxis after epinephrine? How bad is it to give epinephrine for a panic attack? What the heck is Kounis syndrome? Why didn't they teach me this in class? The past ten years have seen a dramatic increase in the number of cases of anaphylaxis across the United States. In response, the American College of Emergency Physicians and the World Allergy Organization have issued im-portant updates on initial emergency treatment for patients suffering from anaphylaxis. While epi-nephrine remains the front-line drug for all levels of care, recent studies show that in-hospital and pre-hospital providers alike aren’t giving it as often or as early as they should. This interactive case-study and pub-quiz style presentation answers these questions and many more with a focus on a rapid differential of anaphylaxis and effective initial and secondary treatments to manage these immediately life-threatening emergencies.
Allergies, a Presentation by Dr. Summit ShahSummit Shah
Dr. Summit Shah presents "Allergies". Dr. Shah is with Premier Allergy in Columbus Ohio. The topics covered are Allergies, Immunotherapy, Medications, Myths and More.
Asthma is the most frequent chronic illness in children and is a common noncommunicable disease (NCD) that affects both adults and children. Coughing, wheezing, chest tightness, and shortness of breath are among the symptoms. This presentation target therapies for Asthma including its clinical use, etc. For more information, please contact us: 9779030507.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Drug induced Anaphylaxis in Latin America
1. DRUG-INDUCED ANAPHYLAXIS IN LATIN
AMERICA
Edgardo J Jares, MD
Vice-President Sociedad Latinoamericana de Alergia Asma e
Inmunología
2. ANAPHYLAXIS
Severe life-threatening generalized or systemic
hypersensitivity reaction
Circulatory collapse and complete
airway blockage can be fatal
Sampson HA, et al. J Allergy Clin Immunol. 2006;117:391-397.
Simons et al. World Allergy Organization Journal 2014, 7:9
3. EPIDEMIOLOGY
Incidence: 3 to 300 per 100 000 person
years
Lifetime prevalence: 0.05-2%
Trend in hospital admission rates for
anaphylaxis by age in England in
1990-2004
(increased 700%)
Panesar SS, et al. Allergy 2013; 68: 1353–1361.
Lieberman P et al. Ann Allergy Asthma Immunol 2006;97:596–602.
Decker WW, et al. J Allergy Clin Immunol 2008;122:1161–1165.
Gupta R et al, Thorax 2007
4. CONCERNS WITH EPIDEMIOLOGICAL DATA
Anaphylactic reactions occur in diverse settings,
are being treated by lay persons or various
medical professionals on site or in medical care
units, and are recognized, diagnosed and
reported differently amongst countries
It’s difficult to gather valid and comparable data
on risk factors, elicitors and treatment details.
Information is best collected in disease-specific
registries
5. FIRST EUROPEAN ANAPHYLAXIS REGISTRY
10 European countries
Online questionnaire
Fifty-nine centers reported 3333 cases of
anaphylaxis (2011-2014)
Pilot study for European Registry
Worm M, et al. First European data from the network of severe
allergic reactions (NORA). Allergy 2014; 69: 1397–1404.
6. EUROPE: MAIN INDUCERS
Foods
20%
Insects
48%
Drugs
23%
Others
9%
79% from
Germany
(yellow
jackets and
bees
Adults
Foods
65%
Childreen
Drugs
5% Others
Insects
20%
10%
34.2% previous, most frequently milder reaction to the same allergen
Worm M, et al. First European data from the network of severe
allergic reactions (NORA). Allergy 2014; 69: 1397–1404.
7. KNOWN ELICITING DRUGS
Cephalosporine
s 9.5%
Penicillin.
13.1%
Antibiotics
28.5%
Quinolones.
5.9%
Diclofenac.
Ibuprofen. 9% 9.3%
Metamizole .
10.2%
Immunotherapy
Radiocontrast
agent. 3%
Local
anaesthetics.
4.9%
. 6.1%
Others. 29 %
NSAIDs:28.5
18.5% previous reaction with the same drug or
group
Worm M, et al. First European data from the network of severe
allergic reactions (NORA). Allergy 2014; 69: 1397–1404.
8. Worm M, et al. First European data
from the network of severe allergic
reactions (NORA). Allergy 2014; 69:
1397–1404.
21% 20%
9. DRUG INDUCED ANAPHYLAXIS
Drug-induced hypersensitivity reactions are a
common yet under-recognized cause of
anaphylaxis
In some studies, drugs are reported as the most
frequent cause of anaphylaxis
Drugs are the most common cause of mortality
due to anaphylaxis in New Zealand and
Australia
Drug anaphylaxis is rarely documented by
allergy testsBanerji A et al. J Allergy Clin Immunol Pract 2014;2:46-
51
Liew WK. J Allergy Clin Immunol 2009;123:434-42
10. SEVERE DRUG-INDUCED ANAPHYLAXIS
Fifty-nine allergists (France) reported 333
cases of severe drug-induced anaphylaxis
Antibiotics
49%
Others
16%
Muscle
relaxants
Immunother.
Latex 11%
2%
4%
CM
4%
NSAIDs
14%
Renaudin J-M, et al. Severe drug-induced anaphylaxis: analysis of 333 cases recorded
by
11. INCRIMINATED DRUGS
beta-lactams
84%
pristinamycin
quinolones
9%
4%
Others
3%
Antibiotics
Renaudin J-M, et al. Severe drug-induced anaphylaxis: analysis of 333 cases recorded
by
12. INCRIMINATED DRUGS: ANTIBIOTICS
9
8
7
6
5
4
3
2
1
0
quinolones
120
100
80
60
40
20
0
beta-lactams
29%
12%
Renaudin J-M, et al. Severe drug-induced anaphylaxis: analysis of 333 cases recorded
by
13. INCRIMINATED DRUGS: NSAIDS
4
2 2
6
14
12
10
8
6
4
2
0
Unknown
Nonimmune
hypersensitivity
IgE-dependent
Renaudin J-M, et al. Severe drug-induced anaphylaxis: analysis of 333 cases recorded
by
14. ANAPHYLAXIS IN AMERICA
Two nationwide, cross-sectional random-digit-
dial surveys: patients and public
Standardized questionnaires
The public survey included 1,000 adults
5.1 and 1.6% probable and very likely
anaphylaxis.
The patient survey included 1,059
respondents: subjects who reported
experiencing some type of generalized
allergic reaction: 32.5% history of
anaphylaxis Wood R et al. J ALLERGY CLIN IMMUNOL
2014
15. ANAPHYLAXIS IN AMERICA
Public Survey Patients Survey
Ever had an allergic reaction
to:
Drugs
34%
Food
16%
Others
24%
Latex
6%
Insects
20%
Drugs.
61%
Insects.
41%
Others/idi
opathic.
Food.
38%
Latex.
13 %
39 %
Wood R et al. J ALLERGY CLIN IMMUNOL
2014
17. ANAPHYLAXIS IN LATIN AMERICA
Online Latin American Survey of Anaphylaxis
(OLASA)
Developed by Latin American Society of
Allergy, Asthma and Immunology
634 patients from 15 countries were
registered
Anaphylaxis online survey in Latin America
Sole D et al. Clinics, 2011 66(6):943-947
18. ANAPHYLAXIS IN LATIN AMERICA
Drugs
34%
Food
23%
Insects
15%
Others
2%
Unknown
26%
Anaphylaxis online survey in Latin America
Sole D et al. Clinics, 2011 66(6):943-947
19. ANAPHYLAXIS IN LATIN AMERICA
94%
79%
40%
30.4%
700
600
500
400
300
200
100
0
Clinical manifestations
Clinical manifestations
Anaphylaxis online survey in Latin America
Sole D et al. Clinics, 2011 66(6):943-947
21. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ARE
MAJOR CAUSES OF DRUG-INDUCED ANAPHYLAXIS
Cutaneous
involvement was
present in 85% of
the cases, and
more than 40% of
the patients had
cardiovascular
dysfunction
Aun M et al J Allergy Clin Immunol Pract 2014;2:414-20)
22. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ARE
MAJOR CAUSES OF DRUG-INDUCED ANAPHYLAXIS
Seventy-eight patients (66.7%) reported previous
reactions to the drug involved in the current reaction
or to a drug from the same class and/or group.
Aun M et al J Allergy Clin Immunol Pract 2014;2:414-20)
23. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ARE
MAJOR CAUSES OF DRUG-INDUCED ANAPHYLAXIS
Epinephrine use: 34%, and less than 50% of
patients with cardiovascular involvement
Aun M et al J Allergy Clin Immunol Pract 2014;2:414-20)
24.
25. 868 HDRs in 862 patients were included in this analysis
3.3%
21.3%
27.3%
45.2%
46.5%
868 HDRs in 862 patients were included in this analysis
26. ANAPHYLAXIS IN LATIN AMERICA
Patients presenting anaphylaxis were
selected in a descriptive cross-sectional
study using ENDA questionnaire
Implemented in 22 allergy units from 11 Latin
American countries
U/A+ R-GI and/or CV Symptoms
Or 2 of the following symptoms:
Respiratory, persistent GI or CV symptoms
From 1005 HDR, 264 presented anaphylaxis
Jares E et al, unpublished
27. ANAPHYLAXIS IN LATIN AMERICA
STRIKING FINDINGS
Severe reactions were present in 43% of
atopic patients and 59% of non-atopic
patients (p<0.01)
Asthma patients has less severe reactions
(38.6%) than non-asthmatic patients (54.6%)
(p<0.05)
Jares E et al, unpublished
28. ASTHMA, ALLERGY AND ANAPHYLAXIS
González Pérez et al (UK) found a 2 fold and 3.3
fold greater risk of anaphylaxis in non-severe
and severe asthmatics respectively
Greenberger PA and Simmons FE:
Severe and uncontrolled asthma → risk factor for
more severe anaphylaxis
Gonzalez Pérez et al. J Allergy Clin Immunol 2010;125:1098-1104
Greenberger PA et al. Annals Allergy, Asthma Immunol, 2007
Simmons FE, J Allergy Clin Immunol 2009
29. DRUG-INDUCED ANAPHYLAXIS TREATED
IN THE EMERGENCY DEPARTMENT OR HOSPITAL
716 patients with an ED visit and/or
hospitalization for DIA
Patients with DIA and atopy or asthma did
not differ with respect to severity, site of
treatment or management compared with
patients without any concomitant allergic
condition
Aun M, and Faria E presented similar
findings
Park H et al did not find difference in
atopy/asthma in anaphylaxis with or without
shock
Banerji A et al. J Allergy Clin Immunol Pract 2014;2:46-51
Aun M et al J Allergy Clin Immunol Pract 2014;2:414-20
Faria E et al. J Investig Allergol Clin Immunol 2014; Vol. 24(1): 40-48
Park H. Am J Emerg Med. 2012 Nov;30(9):1674-8
30. The presumption that atopic predisposition
contributes to a more severe allergic reaction
to drugs, as stated in many publications,
requires further investigation
31. DRUG INDUCED ANAPHYLAXIS IN LATIN
AMERICA
U/A y R-GI: most frequent symptoms
More than 45%: CV involvement
300
250
200
150
100
50
CV symptoms were more frequent in elderly
patients (85%) than in adults (45.7%) and children
(30.6%; p<0.00001)
Jares E et al, unpublished
0
U/A R-GI CV Shock
Elderly
Adults
Children
30.6%
83% 90%
49% 35%
85%
45.7%
32. IN OUR STUDY, SHOCK AND SEVERE ANAPHYLAXIS
WERE MORE FREQUENT IN ELDERLY PATIENTS
In an Australian study of death in anaphylaxis
most drug-induced anaphylaxis deaths
occurred between 55 and 85 years old
patients
Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia.
J Allergy Clin Immunol 2009;123:434-42.
33. IN OUR STUDY, SHOCK AND SEVERE ANAPHYLAXIS
WERE MORE FREQUENT IN ELDERLY PATIENTS
Park et al found that elderly patients with
anaphylaxis were at increased risk for the
development of shock
Park H, Kim S. Factors associated with shock in anaphylaxis. American Journal of
Emergency Medicine (2012) 30, 1674–1678
34. MAIN IMPLICATED DRUGS
(CERTAIN AND PROBABLE)
3%
58%
14%
0 20 40 60 80 100 120 140 160 180 200
Contrasts
Oncological drugs
Allergens
Local anesthetics
Neurological drugs
Steroids
Non beta-lactam antibiotics *
Beta-lactams
NSAIDs
Children
Adults
Elderly
5%
Jares E et al, unpublished
More than 15% of the patients had suffered
a previous HDR with the same drug
35. NSAIDS PREDOMINANCE ΒETA LACTAMS PREDOMINANCE
Latin-America
Sole D et al. Clinics (Sao Paulo).
2011;66(6):943-7
Aun M et al. J Allergy Clin Immunol
Pract. 2014 Jul-Aug;2(4):414-20.
Other regions
Çelik GE, Allergol Immunopathol
(Madr). 2013. (Turkey)
Messaad D et al, Ann Intern Med.
2004;140:1001-1006 (France)
Doña I et al, J Investig Allergol Clin
Immunol. 2012;22:363-371(Spain)
Faria E et al. J Investig Allergol Clin
Immunol 2014; Vol. 24(1): 40-48
(Portugal)
Park H. Am J Emerg Med. 2012
Nov;30(9):1674-8 (Korea)
Gonzalez-Perez A, et al. J Allergy
Clin Immunol 2010;125:1098-
1104. (UK)
Liew WK, et. J Allergy Clin
Immunol 2009;123:434-42.
(Australia)
Cianferoni A et al. Ann Allergy
Asthma Immunol. 2001;87:27-32.
(Italy)
Ribeiro-Vaz I et al. Eur J Clin
Pharmacol. 2013 Mar;69(3):673-
81 (Portugal)
Renaudin J-M et al. Allergy 2013;
68: 929–937. (France)
Worm M, et al. Allergy 2014; 69:
1397–1404. (Europe)
ANAPHYLAXIS INDUCERS
36. DRUG INDUCED ANAPHYLAXIS IN LATIN
AMERICA
30 NSAIDs selective reactivity 1/3
25
20
15
10
5
0
(Renauldin et al: 27%)
Aun MV, et al. J Allergy Clin Immunol Pract. 2014
Faria E et al, . J Investig Allergol Clin Immunol 2014
Quiralte J et al. J Investig Allergol Clin Immunol 2007
Renauldin et al, Allergy 2013
Pyrazolone compounds: 1°
cause, similar to Brazil
(Aun et al), different to
Portugal (Faria et al) and
Spain (Quiralte et al)
Jares E et al, unpublished
37. DIAGNOSTIC TESTING PERFORMED
160
140
120
100
80
60
40
20
0
SPT ICT DPT
positive
negative
22.7%
11.4%
48%
42.8%
31.5%
41%
Jares E et al, unpublished
38. TREATMENT: 78% WERE TREATED IN THE EMERGENCY
DEPARTMENT, AND 8.7% HOSPITALIZED
0 10 20 30 40 50 60 70 80 90
Oxigen
Intravenous Fluids
Bronchodilators
Epinefrine
Corticosteroids
Antihistamines
Elderly
Adults
Epinephrine Children
% % % % % % % % %
Jares E et al, unpublished
Only 27% of anaphylaxis patients
recieved epinephrine, 39.2%
when CV symptoms were
present
39. EPINEPHRINE USE
The low epinephrine use in anaphylaxis
treatment is common in studies from Latin
America and other regions
Klemans et al (Netherlands): only 27% of
patients with food anaphylaxis and
respiratory symptoms treated by general
practitioners received epinephrine. This rate
increased to 73% when there was CV
involvement.
Klemans RJ, Le TM, Sigurdsson V, et al. Management of acute food allergic reactions
by general practitioners. Eur Ann Allergy Clin Immunol. 2013;45:43-51
40. EPINEPHRINE USE
Banerji et al: only 8% of patients with drug-induced
anaphylaxis treated in the ED
received epinephrine
Banerji A, Rudders S, Clark S, Wei W, Long A, Camargo C. Retrospective study of drug-induced
anaphylaxis treated in the emergency department or hospital: patient
characteristics, management, and 1-year follow-up. J Allergy Clin Immunol Pract.
2014;2:46-51.
41. CONCLUSIONS
The relationship between atopic
predisposition/asthma and anaphylaxis
requires further investigation
NSAIDs are the most frequent anaphylaxis
inducers in Latin-America
Epinephrine is underuse in anaphylaxis
treatment in Latin America and other regions
Medical education of ED physicians in Latin
America should focus on this topic